Expert perspectives on life sciences strategy, commercialization, and market dynamics.
Expert perspectives on life sciences strategy, commercialization, and market dynamics.
A Practical Guide to Protect GTN, Expand Access, and Improve Patient Experience On July 31, 2025, the White House escalated U.S. drug pricing pressure by sending letters to 17 pharmaceutical CEOs demanding concrete steps to align U.S. prices with “most favored nation” (MFN) levels. At the same time, affordability pressure is rising from the bottom […]
Value Drivers to Enable and Elevate a Successful Raise The shift in the cell and gene therapy capital market may not be shocking to those who have been watching since the post-COVID zeitgeist, when market entry of several clinical successes finally came after decades of innovation and development in the field. Slow clinical progress of […]
Challenging post-launch market access is one of the biggest contributors to missed forecasts in recent pharmaceutical launches. Manufacturers launching new therapies are grappling with a variety of strategic choices under the market access umbrella. They’re dealing with optimization of initial coverage, rebate strategy, and affordability programs to mitigate patient out-of-pocket costs. They are also contending […]
Four Lessons Learned from Adalimumab As manufacturers seek to capitalize on blockbuster biologic LOEs in the coming years, the adalimumab market has proven that a successful biosimilar launch is not guaranteed. Biosimilars began entering the market about 18 months ago. Despite early access being achieved by leading competitors, Humira’s position in the market and likely […]